Dr. Mazen Noureddin

---

Residency: University of Southern California, 2005

Fellowship: National Institutes of Health, 2008

Master's: Duke University School of Medicine, 2009

Fellowship: University of California, San Diego School of Medicine, 2011

The research of Mazen Noureddin, MD, focuses on the underlying mechanisms of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), new imaging modalities and exploring new treatments. He has conducted several original studies that have been featured in publications such as Gastroenterology, Hepatology and The American Journal of Gastroenterology, among many others. The Fatty Liver Program at Cedars-Sinai has many breakthrough clinical trials targeting new therapies in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitisn (NASH), including those with advanced fibrosis and cirrhosis.